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Two novel 1a-hydroxylase mutations in French-Canadians with
vitamin D dependency rickets type I.
Background. Vitamin D dependency rickets type I (VDDR-I) is
an autosomal recessive disorder in which 25-hydroxyvitamin D
1a-hydroxylase (1a-hydroxylase) activity in renal proximal tubules
is deficient. VDDR-I is recognized throughout the world, but
occurs more frequently in a subset of the French-Canadian
population. We and others have recently cloned the human
1a-hydroxylase cDNA and gene, making it possible to screen for
mutations. The first VDDR-I mutations were reported in one
American and four Japanese patients. In this study, we screened
for 1a-hydroxylase mutations in French-Canadian patients with
VDDR-I.
Methods. The nine exons of the 1a-hydroxylase gene were
amplified by polymerase chain reaction (PCR) from genomic
DNA of four unrelated French-Canadian patients with VDDR-I
and their parents, and sequenced.
Results. Three of the patients were homozygous for a single
base-pair deletion (G) at position 262 in the cDNA that lies in
exon 2, and causes a premature termination codon upstream from
the putative ferredoxin- and heme-binding domains. The fourth
patient was homozygous for a 7-bp insertion (CCCCCCA) at
position 1323 of the cDNA that lies in exon 8, and causes a
premature termination upstream from the putative heme-binding
domain. In each family, obligate carriers have one copy of the
mutant allele. These mutations, which could be detected by
PCR-restriction fragment length polymorphism and polyacryl-
amide gel electrophoresis of the PCR products, were not found in
25 normal French-Canadians.
Conclusion. We describe two novel 1a-hydroxylase mutations
that are consistent with loss of function in four French-Canadian
patients with VDDR-I and suggest that the 1a-hydroxylase mu-
tations arise from more than one founder in this population.
Vitamin D dependency rickets type I (VDDR-I), also
referred to as pseudo-vitamin D deficiency rickets, is an
autosomal recessive disorder characterized by early onset
of hypocalcemia, hypophosphatemia, secondary hyperpara-
thyroidism, and severe rachitic lesions [1, 2]. The serum
concentrations of 1a, 25-dihydroxyvitamin D [1a,25(OH)2D]
are low or undetectable despite normal or slightly elevated
concentrations of 25-hydroxyvitamin D [25(OH)D] [3]. The
clinical phenotype is completely corrected by the administra-
tion of physiological doses of 1a,25(OH)2D [4, 5]. Thus,
VDDR-I is presumed to result from impaired synthesis of
1a,25(OH)2D. Although VDDR-I is rare, the disease occurs
at an unusually high frequency in the French-Canadian pop-
ulation [6]. It was attributed to a founder effect that had taken
place in the second half of the seventeenth century, when a
small number of colonists emigrated to Que´bec from northern
France. Linkage analysis in French-Canadian families with
VDDR-I demonstrated that the disease locus maps to
12q13-14 [7, 8].
The synthesis of 1a,25(OH)2D from its endogenous
precursor, 25(OH)D, is catalyzed by 25-hydroxyvitamin D
1a-hydroxylase (1a-hydroxylase), a mitochondrial cyto-
chrome P450 enzyme that functions in renal proximal
tubular cells [9]. Although it is the key enzyme in vitamin D
metabolism, the cloning of 1a-hydroxylase has been diffi-
cult due to low levels of gene expression. Recently, we and
other investigators have succeeded in the molecular cloning
of rat [10, 11], mouse [12], and human [13–15] 1a-hydrox-
ylase cDNAs. We and others have also cloned the human
1a-hydroxylase gene and demonstrated that it is comprised
of nine exons [13, 15, 16]. The human 1a-hydroxylase
cDNA consists of 2469 bp, and encodes a deduced protein
of 508 amino acids containing a ferredoxin-binding domain
and a heme-binding domain. It shares a relatively high
homology with vitamin D 25-hydroxylase. The availability
of the cDNA and gene structure now makes it possible to
analyze for mutations in the 1a-hydroxylase gene in
VDDR-I patients.
1 See Editorial by Portale and Miller, p. 1762.
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Recently, 1a-hydroxylase mutations have been identified
in a single patient from California [14] and in four Japanese
patients from Japan [15]. It is not yet known whether these
particular mutations also account for VDDR-I in other
populations such as French-Canadians where the disease
frequency is remarkably high. In this study, we report the
first French-Canadian 1a-hydroxylase mutations and show
by fluorescence in situ hybridization (FISH) that the gene
maps to the same 12q13-14 locus linked to French-Cana-
dian VDDR-I [7, 8]. These mutations are novel and suggest
more than one founder for VDDR-I in the French-Cana-
dian population.
METHODS
Fluorescence in situ hybridization
The screening of a human P1 library (Genome Systems
Inc., St. Louis, MO, USA) was performed by polymerase
chain reaction (PCR). Primers were designed within exon 5
of human 1a-hydroxylase (EX5F; 59-GTGTCCACTC-
CCGCCAATAGC-39, EX5R; 59-CAGCCATGAGGAA-
CGGAGGACAG-39) [13]. Four positive clones were iso-
lated. We confirmed the partial sequence of the clones, and
then used clone F499 of 85 kb long for FISH analysis. The
P1 clone F499 was labeled with digoxigenin dUTP by nick
translation. Labeled probe was combined with sheared
human cDNA and hybridized to normal metaphase chro-
mosomes derived from phytohemagglutinin-stimulated pe-
ripheral blood lymphocytes in a solution containing 50%
formamide, 10% dextran sulfate, and 23 standard saline
citrate (SSC). Specific hybridization signals were detected
by incubating the slides with fluoresceinated antidigoxige-
nin antibodies. Chromosomes were counterstained with
propidium iodide (1 mg/ml), banded with 4, 6-diamidino-2-
phenylindole (DAPI).
Subjects
Four unrelated VDDR-I families (Fig. 1) and 25 normal
controls from Que´bec, Canada, were enrolled in this study.
The parents of patient A1 are of Irish and French-Cana-
dian background, whereas family B, family C, and family D
are French-Canadians. Blood samples were obtained from
individuals after informed consent had been obtained.
Direct sequencing analysis
The nine exons of the 1a-hydroxylase gene were com-
pletely sequenced in all patients. Each exon except for exon
2 was amplified by PCR using 10 sets of specific primers
(Table 1). An M13 primer (59-CAGGAAACAGCTAT-
GAC-39) was added to each synthetic forward primer to
permit direct sequencing of PCR products. PCR was
performed in a solution (50 ml) containing 0.2 mmol/liter
dNTPs, 1.5 mmol/liter MgCl2, 50 mmol/liter KCl, 10 mmol/
liter Tris-HCl (pH 8.3), 1 mmol/liter of each pair of primers,
5 ng genomic DNA extracted from the blood samples, and
1.25 U Taq polymerase (Takara Shuzo Co., Ltd., Shiga,
Japan). PCR was programmed as follows: denaturing at
93°C for one minute, annealing at 67°C for two minutes,
and extension at 72°C for two minutes for 30 cycles. The
Fig. 1. Pedigrees of the families with vitamin D
dependency rickets type I.
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PCR products were electrophoresed, and the bands of the
expected size were isolated. The resultant samples were
sequenced using the M13 primer and an ABI Dyedeoxy
Terminator Cycle Sequencing kit (Applied Biosystems,
Foster City, CA, USA), and analyzed on an automated
DNA sequencing system (model 373A, Applied Biosys-
tems). For exon 2, DNA fragments were amplified using
h1Aex1-forward and h1Aex3-reverse primers, because we
failed to amplify the target DNA directly using h1Aex2-
forward and -reverse primers. The PCR products encom-
passing exon 1 to exon 3 were sequenced using h1Aex2-
forward and -reverse primers, respectively.
Restriction fragment length polymorphism (RFLP)
DNA fragments containing exon 2 were obtained by an
initial round of PCR using h1Aex1-forward and h1Aex3-
reverse primers, followed by the nested PCR using h1Aex2-
forward and h1Aex2-reverse primers. The PCR products of
310 bp were digested with Mae II (Boehringer Mannheim,
Corp., Indianapolis, IN, USA) at 50°C for 24 hours, and the
samples were separated by 3% agarose gel electrophoresis
and visualized by ethidium bromide staining. The PCR
products analyzed were from the members of families A, C,
and D, and normal controls.
Polyacrylamide gel electrophoresis
For exon 8, genomic DNA was amplified by PCR using
h1Aex8-forward and -reverse primers. PCR products de-
rived from family B and normal controls were electropho-
resed on an 8% denatured polyacrylamide gel, and were
stained with ethidium bromide.
RESULTS
Chromosomal localization
A P1 clone including the human 1a-hydroxylase gene,
referred to as F499, was used as a probe for FISH analysis.
FISH analysis resulted in specific labeling of the proximal
long arm of a group C chromosome which was believed to
be chromosome 12 on the basis of size, morphology, and
banding pattern (Fig. 2A). This was confirmed by cohybrid-
ization with a probe previously mapped to the short arm of
chromosome 12. Analysis of 10 specifically labeled chromo-
some 12s demonstrated that F499 is located at a position
that is 24% of the distance from the centromere to the
telomere of chromosome arm 12q, an area that corresponds
to band 12q13.2-13.3 (Fig. 2B). A total of 80 metaphase
cells were analyzed with 71 exhibiting specific labeling.
Characteristics of the VDDR-I patients
Four unrelated VDDR-I families from Que´bec, Canada,
participated in the study. As shown in Table 2, the first
symptoms in four patients with VDDR-I appeared within
the first year of life, although all patients were healthy at
birth. All had signs of active rickets on radiological exam-
ination of wrist and knees. Their serum calcium was low,
and serum phosphorus was normal or low. Serum alkaline
phosphatase activity was elevated. PTH and vitamin D
assays were not available on all patients. Serum calcium was
normalized in response to therapy with 1a,25(OH)2D3.
Currently all patients exhibit normal blood chemistries
while on treatment with physiological doses of 1a,25(OH)2D3
(12 to 18 ng/kg/day), and all signs of radiological rickets have
resolved. In patients B1, C1, and D1, serum 1a,25(OH)2D3
levels were extremely diminished (,17 pg/ml), when medica-
tion was stopped for one to three weeks, confirming the
diagnosis of VDDR-I.
Mutations in the 1a-hydroxylase gene in VDDR-I
patients
Each exon of the 1a-hydroxylase gene was amplified by
PCR from genomic DNA of four unrelated VDDR-I
patients and their parents (Table 1). This approach ampli-
fied all exons containing the coding region, the 39-untrans-
lated region of cDNA, ;150 bp upstream from the start
codon, and the exon-intron boundaries. By direct sequenc-
ing of the resultant PCR products, two distinct 1a-hydrox-
ylase gene mutations were encountered in the VDDR-I
probands examined.
In probands A1, C1, and D1, a single base-pair (G)
deletion was identified at position 262 (262del1) in the
1a-hydroxylase cDNA (Fig. 3A), which lies in exon 2 of the
gene. This mutation is homozygous in all three affected
Table 1. PCR primers for direct sequencing of the human 25-hydroxyvitamin D 1a-hydroxylase gene
Primer name Exon Forward primer Reverse primer
h1Aex1 1 AGCCCCGCCTACTGTTCCTGG CAAAACCAGTTTCCCCAGCAC
h1Aex2 2 ACAGGTCAAGCTGAAAGTCCC ATAGTTTCGGGACCCGCAGC
h1Aex3 3 GTCGAGCCGTCCCCACCTTCC GCTCTGGTAGGGCGCCCCCGA
h1Aex4 4 GCGCCCTACCAGAGCCTCCCG CCCCTGGACAGCTTTACATTC
h1Aex5 5 TAAAGCTGTCCAGGGGTAGCG GCGGAGGCTAAGCCCTGGAAC
h1Aex6 6 CTGCTGGGTTCTCACACCCAA CCAGCCCTTCCTTGGCATTTC
h1Aex7 7 GCAGCCCCTAGCCTCATCTTG CAAGATAGTGAGGAATGGCTC
h1Aex8 8 CCTGCCCTATTCTGAGCCCAA GGGTTAGGGTCTCTCCAGTCT
h1Aex9A 9 TATCTTTCATAGTAATGCTCACC ATACATGATCAGAAGGGCCAAG
h1Aex9B 9 CGGCCCTGACCAATGTGTGAA CCTTCTGCCACATGGTTCAGA
h1Aex9C 9 TATGTCCCCTGCCAGGGCCTG TCCAGGTCTTGTAGGAAGTGG
Primers are all within introns with the exception of h1Aex9A-reverse, h1Aex9B-forward, h1Aex9B-reverse, and h1Aex9C-forward, which lie within
exon 9.
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Fig. 2. Chromosomal mapping of the human 25-hydroxyvitamin D 1a-hydroxylase gene. (A) Fluorescence in situ hybridization analysis using F499
probe to 46, XY metaphases. Arrows indicate the specific signals. A probe for the short arm of chromosome 12 was cohybridized. (B) Two ideograms
illustrating the chromosomal position of clone F499 at 12q13.2-13.3.
individuals. It is predicted to result in a frameshift leading
to an altered amino-acid sequence from codon 88, followed
by a stop at codon 157. The deduced protein is significantly
truncated upstream from the putative ferredoxin- and the
putative heme-binding domains. In each of the families, the
exon 2 PCR products derived from the parents (A3, C2,
D2; Fig. 1) were also directly sequenced. Obligate carriers
were found to be heterozygous for the corresponding
mutation (Fig. 3B). We confirmed that the parents of
probands A1, C1, and D1 were heterozygous for the
mutation by subcloning the PCR products into pT7-Blue T
vector (Novagen, Madison, WI, USA) and sequencing
(data not shown). Control subjects were homozygous for
the normal sequence (Fig. 3C).
We performed PCR-RFLP analysis on exon 2 of the
gene. While the wild-type sequence has a Mae II restriction
site in exon 2, a single base-pair (G) deletion at position
262 removes this restriction site (that is, ACGT to ACT).
To amplify exon 2, we first amplified the DNA fragment
encompassing exon 1 to exon 3, and then obtained a 310-bp
fragment by nested PCR using h1Aex2-forward and -re-
verse primers. In normal subjects, the resultant PCR prod-
uct of 310 bp was digested into 194 bp and 116 bp with Mae
II (Fig. 4). In patients A1, C1, and D1, the PCR product
had no Mae II restriction site and was detected as a single
band (309 bp). Moreover, following Mae II digestion of
PCR products derived from parents of these patients,
three bands (309 bp, 194 bp, and 116 bp) were detected.
PCR-RFLP analysis clearly showed that the patients and
their parents were respectively homozygous and heterozy-
gous for the single base-pair deletion in exon 2. We also
examined the exon 2 PCR products derived from 25 normal
French-Canadians by PCR-RFLP analysis and found no
mutant alleles (data not shown).
In proband B1, a 7-bp insertion (CCCCCCA) at position
1323 was found in the 1a-hydroxylase cDNA (1323insC-
CCCCCA) (Fig. 3D). This insertion lies in exon 8, and
causes a frameshift at codon 443 and a premature trunca-
tion of the protein at codon 465, downstream of the
putative ferredoxin-binding domain and upstream of the
putative heme-binding domain. Both parents of proband
B1 were shown to be heterozygous for the mutation by
direct sequencing of exon 8 PCR products (Fig. 3E). These
data were confirmed by subcloning the PCR products from
both parents into pT7-Blue T vector and sequencing (data
not shown).
We were able to detect the 7-bp insertion in the B
kindred by 8% denatured polyacrylamide gel electrophore-
sis of PCR-amplified exon 8. The PCR product derived
from a normal control has a predicted size of 297 bp (Fig.
5). The PCR product derived from patient B1 was 7-bp
longer than that from a normal control. Moreover, two
PCR products were detected in B1’s father (B2), one of 297
bp and one of 305 bp. These data confirm that the proband
and obligate carrier are homozygous and heterozygous for
the corresponding mutation, respectively. The PCR prod-
ucts derived from 25 normal French-Canadians were exam-
ined by polyacrylamide gel electrophoresis and no mutant
alleles were found (data not shown).
DISCUSSION
VDDR-I is a rare Mendelian disorder with phenotypic
features of vitamin D deficiency and can be treated with
physiological doses of 1a,25(OH)2D but not 25(OH)D [4,
5]. While this feature provides indirect evidence for a
defect in renal 1a-hydroxylase activity, elucidation of the
precise genetic mechanism for impaired 1a,25(OH)2D
biosynthesis in VDDR-I patients required further study.
Fig. 4. RFLP analysis of exon 2 in families A,
C, and D. The PCR products containing exon 2
were digested with Mae II, and then were
electrophoresed on a 3% agarose gel. A1,
patient A1; A3, A1’s mother; C1, patient C1;
C2, C1’s father; D1, patient D1; D3, D1’s
father; N1-N3, normal controls.
Table 2. Characteristics of patients with VDDR-I
A1 B1 C1 D1 Normal range
Onset months 7 5 7 7
Serum calcium mg/dl 5.2 7.1 6.4 7.1 8–10
Serum phosphorus mg/dl 4.0 1.6 4.3 4.4 3.5–5.5
Serum alkaline phosphatase IU/liter 636 2120 2025 ND 130–300
Serum PTH pg/ml ND 210 660 124 10–65
Serum 1a,25 (OH)2D pg/ml ND ,17 ,17 ,17 35–100
ND is not determined.
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Fig. 3. The 25-hydroxyvitamin D 1a-hydroxylase gene mutations in vitamin D dependency rickets type I. Genomic DNA was amplified by PCR, and
then directly sequenced. On the left, sequence data of exon 2 (sense strand) are shown for VDDR-I patient A1 (A), A1’s mother A3 (B), and normal
control (C). A single base-pair deletion (G) at position 262 is detected in the patient. Similar results were obtained for families C and D. On the right,
sequence data of exon 8 (sense strand) are shown for VDDR-I patient B1 (D), B1’s mother B3 (E), and normal control (F). A 7-bp insertion
(CCCCCCA) at position 1323 is detected in the patient. Arrows and underlines indicate the positions of the mutations.
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The recent cloning of the human 1a-hydroxylase cDNA
[13–15] and gene [13, 15, 16] by our group as well as others
has made it possible to screen for mutations in the 1a-
hydroxylase gene in VDDR-I patients. Indeed, DNA anal-
ysis of one American female with VDDR-I revealed dele-
tion/frameshift mutations at codons 211 and 231 of the
1a-hydroxylase cDNA and showed that the patient was a
compound heterozygote for the two null mutations [14].
Molecular studies on the proband’s parents were, however,
not reported. Kitanaka et al also analyzed four Japanese
patients with VDDR-I, and found four different homozy-
gous missense mutations in the 1a-hydroxylase gene [15].
To determine whether these findings could be extrapolated
to other patient populations with VDDR-I, we screened for
1a-hydroxylase mutations in four unrelated probands of
French-Canadian origin.
VDDR-I occurs at an unusually high frequency in
French-Canadians [6] and the disease locus in this popula-
tion was mapped to chromosome 12q13-12q14 by linkage
analysis [7, 8]. In the present study, we also confirmed that
the 1a-hydroxylase gene maps to human chromosome
12q13.2-q13.3 by FISH, and this result is consistent with
those of St-Arnaud et al [11] and Kitanaka et al [15].
In this study, we have identified two novel mutations in
the 1a-hydroxylase gene. Three unrelated VDDR-I pro-
bands (A1, C1, and D1) had a single base-pair deletion at
position 262 (262del1) in the cDNA that results in a
frameshift mutation leading an altered amino acid se-
quence from codon 88, followed by a stop at codon 157.
The deduced protein is significantly truncated (88 of 508
amino acids) and has neither the putative ferredoxin- nor
the putative heme-binding domains [13]. The fourth pro-
band (B1) has a 7-bp insertion at position 1323 (1323insC-
CCCCCA) in the 1a-hydroxylase cDNA. This insertion
creates a tandem repeat (CCCCCCA CCCCCCA) that
may have occurred by slipped strand mispairing [17]. The
deduced protein product is truncated and lacks the putative
heme-binding domain.
Both 1a-hydroxylase mutations that we identified are
novel and are likely responsible for the VDDR-I pheno-
type. Each of the probands is homozygous for his/her
respective mutation and each mutation results in a trun-
cated protein that lacks critical domains essential for
catalytic activity. This conclusion is supported by the clini-
cal severity and phenotypic similarity among the four
VDDR-I probands studied. Moreover, our findings are
consistent with the previous data [14, 15]. Fu et al demon-
strated that cultured keratinocytes, derived from an Amer-
ican compound heterozygote with deletion/frameshift mu-
tations at codons 211 and 231 of the 1a-hydroxylase cDNA,
had no detectable 1a-hydroxylase activity, although robust
1a,25(OH)2D production was evident in cultured keratin-
ocytes derived from normal individuals [14]. Kitanaka et al,
who found four homozygous mutations (Arg107His,
Gly125Glu, Arg335Pro, and Pro382Ser) in four Japanese
patients with VDDR-I, also demonstrated that the mutant
1a-hydroxylase proteins expressed in COS cells were de-
void of 1a-hydroxylase activity [15].
The parents of the VDDR-I probands that we examined
are obligate carriers and, in each case, we confirmed that
they had one copy of the mutant allele identified in their
affected offspring. In contrast, the two novel 1a-hydroxy-
lase mutations that we identified were not present in 25
normal French-Canadian controls, who by definition are
homozygous for the normal sequence. On the basis of the
inheritance pattern and the severity of the mutations, it
seems reasonable to conclude that both novel mutations
are responsible for VDDR-I in the families studied.
VDDR-I is unusually frequent in a subset of French-
Canadians in Que´bec, Canada [6]. DeBraekeleer estimated
that the prevalence of VDDR-I is 1 in 2358 live births,
giving a carrier rate of 1/26 in the Charlevoix-Saguenay-
Lac-Saint-Jean region of Que´bec [18]. It was attributed to
a founder effect that had taken place in the second half of
the seventeenth century. Labuda et al demonstrated that
French-Canadians from the Charlevoix-Saguenay-Lac-
Saint-Jean area of Que´bec who are VDDR-I carriers have
a different haplotype at the VDDR-I locus than Acadian
French-Canadian carriers from Prince Edward Island and
New Brunswick [8]. It is of interest that the families of
patients A, C, and D who are homozygous for the single
base-pair deletion originate from Que´bec whereas the
parents of patient B, who is homozygous for the 7-bp
insertion, moved to Que´bec from New Brunswick. Accord-
ingly, it is possible that the mutation in families A, C, and
D originate from the Charlevoix-Saguenay-Lac-Saint-Jean
founder whereas the mutation in family B originates from
the Acadian founder. While further work is necessary to
determine the haplotypes of our patients and to assess the
frequency of these mutations in the French-Canadian
population, our findings are consistent with the notion that
the 1a-hydroxylase mutations that we described arose from
two founders [8]. However, since the 7-bp insertion was
identified in a single family, it could represent undetected
consanguinity within this isolated family rather than origi-
nate from the second founder described by Labuda et al [8].
The two novel mutations that we identified can be easily
detected by PCR-RFLP analysis and polyacrylamide gel
electrophoresis of the PCR products. Screening for these
mutations in French-Canadian patients with VDDR-I will
clarify this issue.
Fig. 5. Polyacrylamide gel electrophoresis of the PCR products across
exon 8 in family B. Genomic DNA was amplified by PCR using h1Aex8-
forward and h1Aex8-reverse primers. PCR products were electrophoresed
on an 8% denatured polyacrylamide gel and stained with ethidium
bromide. B1, patient B1; B2, B1’s father; N1, normal control.
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In conclusion, we have identified two novel homozygous
mutations in the 1a-hydroxylase gene in four unrelated
French-Canadian patients with VDDR-I. Both mutations
result in truncated proteins and are likely responsible for
the VDDR-I phenotype. Our results demonstrate that not
all the French-Canadian patients carry the same mutation,
and suggest that there is more than one founder for the
1a-hydroxylase mutations in this population.
NOTE ADDED IN PROOF
After submission this manuscript, the Cytochrome P450
Gene Superfamily Nomenclature Committee decided to
name the mammalian 25-hydroxyvitamin D 1a-hydroxylase
gene “CYP27B1.”
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